为您找到相关结果约500个

你是不是要搜索 期刊R2诱导后维持治疗复发/难治性惰性NHL的MAGNIFY IIIb期研究中期分析 点击跳转

MAGNIFY phase IIIb interim analysis of induction R-2 followed by maintenance in relapsed/refractory indolentNHL.

Response rate to lenalidomide plus rituximab (R-2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.

MAGNIFY: Phase IIIb interim analysis of induction R-2 followed by maintenance in relapsed/refractory

Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis ofInduction R-2 Followed By Maintenance

Magnify: A Phase IIIB Trial Shows Promising Efficacy in the Treatment of Relapsed/Refractory, IndolentNon-Hodgkin Lymphoma Patients with Lenalidomide in Combination with Rituximab (R-2)

Phosphorescence in Mn4+-Doped R+/R2+ Germanates (R+ = Na+ or K+, R2+= Sr2+)

PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS.RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS

Subgroup Analyses of Elderly Patients Aged >= 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of InductionR-2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Phase IIIb randomized study of lenalidomide plus rituximab (R-2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL

THE MAGNIFY-MS STUDY: MAVENCLAD (R) TABLETS IN ACTIVE RMS

Efficacy and time to next treatment following lenalidomide/rituximab (R-2) or rituximab/placebo in patientswith R/R indolent NHL (AUGMENT).

Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel(JCAR017) in R/R aggressive NHL.

Updated Safety and Long-Term Clinical Outcomes in TRANSCEND NHL 001, Pivotal Trial of Lisocabtagene Maraleucel(JCAR017) in R/R Aggressive NHL

Exploring Potential Germline-Associated Roles of the TRIM-NHL Protein NHL-2 Through RNAi Screening

R-CHOP can be safely de-escalated in NHL

为您找到相关结果约500个

共500条页码: 1/34页15条/页